Golgi Apparatus‐Targeting Immunostimulant for Synergistic Activation of Antitumor Immunity via Pyroptosis Induction and PD‐L1 Degradation
Advanced Healthcare Materials · 2026-05 · 15 (17)
DOI: 10.1002/adhm.202504895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 17.02.2026. Verfasst von Rong-Rong Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the Sc…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Golgi Apparatus, Pyroptosis, Adjuvants, Immunologic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
The inherently low immunogenicity and immune evasion properties of breast cancer cells present major obstacles to the effective activation of antitumor immune responses. To overcome these challenges, we develop a Golgi apparatus‐targeting immunostimulant (GA‐IS) that synergistically enhances antitumor immunity through the induction of pyroptosis and degradation of PD‐L1. GA‐IS is based on an amphiphilic chimeric peptide (GA‐Chip), which consists of a Golgi apparatus‐targeting sequence (SDYQRL), a hydrophobic palmitic acid moiety, and the photosensitizer protoporphyrin IX (PpIX). This construct is co‐formulated with the PD‐L1 degrader dBET57 using DSPE‐PEG 2000 to improve stability and systemic delivery. Upon accumulation in tumor cells, GA‐IS enables precise drug delivery to the Golgi apparatus and elicits localized photodynamic effects, thereby inducing pyroptotic cell death and robust immunogenic cell death (ICD), ultimately enhancing tumor immunogenicity. Critically, GA‐IS also downregulates PD‐L1 expression via BRD4 degradation, effectively disrupting immune checkpoint signaling and restoring immune surveillance. As a result, GA‐IS elicits a potent systemic immune response capable of suppressing both primary and metastatic breast cancer, while showing minimal systemic toxicity. This Golgi apparatus‐targeting immunostimulant represents a promising strategy to reverse immune suppression in breast cancer and advance precision immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzh…
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China.
- Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Shi-Ying Li
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Guangdong Basic and Applied Basic Research Foundation
- Postdoctoral Fellowship Program of CPSF
- National Medical Research Council (NMRC) Open Fund-Individual Research
- National Research Foundation (NRF) 28th Competitive Research Programme
- Postdoctoral start-up funding of Guangzhou Medical University
- Open Project of State Key Laboratory of Respiratory Disease
Zitieren
APA
Zheng, R. R., Li, Q. Y., Zhang, S. Y., Zhou, H. Y., Chen, G. M., Liu, Y. X., Lu, L. C., Huang, C. Y., Ye, Y., Ding, L. W., Zhao, L. P., & Li, S. Y. (2026). Golgi Apparatus‐Targeting Immunostimulant for Synergistic Activation of Antitumor Immunity via Pyroptosis Induction and PD‐L1 Degradation. Advanced Healthcare Materials, 15(17). https://doi.org/10.1002/adhm.202504895
Vancouver
Zheng RR, Li QY, Zhang SY, Zhou HY, Chen GM, Liu YX, et al. Golgi Apparatus‐Targeting Immunostimulant for Synergistic Activation of Antitumor Immunity via Pyroptosis Induction and PD‐L1 Degradation. Advanced Healthcare Materials. 2026;15(17). doi:10.1002/adhm.202504895
BibTeX
@article{Zheng2026,
author = {Zheng, Rong-Rong and Li, Qiu-Yuan and Zhang, Shui-Ying and Zhou, Hang-Yu and Chen, Guang-Miao and Liu, Yi-Xin and Lu, Li-Chong and Huang, Chu-Yu and Ye, Yun and Ding, Ling-Wen and Zhao, Lin-Ping and Li, Shi-Ying},
title = {Golgi Apparatus‐Targeting Immunostimulant for Synergistic Activation of Antitumor Immunity via Pyroptosis Induction and PD‐L1 Degradation},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {17},
doi = {10.1002/adhm.202504895}
}
EUVIMED